These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32333937)

  • 1. 11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis.
    Gregory S; Hill D; Grey B; Ketelbey W; Miller T; Muniz-Terrera G; Ritchie CW
    Metabolism; 2020 Jul; 108():154246. PubMed ID: 32333937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
    Scott JS; Goldberg FW; Turnbull AV
    J Med Chem; 2014 Jun; 57(11):4466-86. PubMed ID: 24294985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome.
    Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M
    Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
    Loerz C; Maser E
    J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome.
    St Jean DJ; Wang M; Fotsch C
    Curr Top Med Chem; 2008; 8(17):1508-23. PubMed ID: 19075762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
    Morgan SA; Tomlinson JW
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
    Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel
    Baum E; Zhang W; Li S; Cai Z; Holden D; Huang Y
    ACS Chem Neurosci; 2019 May; 10(5):2450-2458. PubMed ID: 30689943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
    Cooper MS; Stewart PM
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
    Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
    Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
    Hong SP; Han D; Chang KH; Ahn SK
    Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.